Amlodipine for Elderly Female Patients with CKD 3b

Guideline-Based Blood Pressure Targets

The American College of Cardiology and the Kidney Disease: Improving Global Outcomes guideline recommend a target blood pressure of <130/80 mmHg for patients with CKD stage 3b 1, 2.
The Kidney Disease: Improving Global Outcomes 2021 guideline emphasizes that a systolic blood pressure target of <120 mmHg provides cardioprotective and survival benefits, though individualization is important in elderly patients 1.
The American College of Cardiology recommends a systolic blood pressure <130 mmHg for noninstitutionalized, ambulatory, community-dwelling adults ≥65 years if tolerated 3.

Amlodipine demonstrated equivalent cardiovascular outcomes to chlorthalidone in the ALLHAT trial among 5,545 hypertensive patients with eGFR <60, with hazard ratios of 1.01 for CV death and 0.86 for coronary heart disease 4.
The CASE-J trial showed amlodipine was as effective as candesartan in reducing cardiovascular events in Japanese patients with hypertension and CKD stage 3, with a hazard ratio of 1.01 4.

Women display faster drug clearance of amlodipine than men due to higher CYP3A4 activity, but this clearance decreases with age, resulting in greater blood pressure reduction in older women 5.
Peripheral edema is the most common side effect and occurs more frequently in women, which may affect adherence 5.
Starting with amlodipine 2.5-5 mg daily is appropriate for elderly patients, with gradual titration as needed 6.

If the patient has albuminuria ≥300 mg/day, an ACE inhibitor or ARB should be the preferred first-line agent, with amlodipine added as second-line therapy if blood pressure remains uncontrolled 5, 6.
For patients without significant albuminuria, amlodipine can be used as first-line therapy or in combination with a thiazide diuretic 6.
Never combine an ACE inhibitor with an ARB, as this increases adverse events without additional benefit 5, 3.

Check blood pressure, serum creatinine, and electrolytes within 2-4 weeks after initiating amlodipine 5, 6.
Continue monitoring every 3-6 months depending on stability 5.
An initial small decline in GFR (10-20%) after starting antihypertensive therapy is acceptable and does not require discontinuation unless accompanied by hyperkalemia or excessive decline 5.
Screen for orthostatic hypotension by measuring blood pressure in both sitting and standing positions in elderly patients 6.

Watch for peripheral edema, which may require dose reduction or addition of an ACE inhibitor/ARB 5.
Monitor for symptomatic hypotension, particularly in elderly patients 3.
If blood pressure control is inadequate with amlodipine monotherapy, consider adding a thiazide diuretic or an ACE inhibitor/ARB depending on the presence of albuminuria 6.